MSI-H 英语是什么意思 - 英语翻译

• MSI-H

在 中文 中使用 Msi-h 的示例及其翻译为 英语

Lynch综合征患者的肿瘤表现为MSI-H。
The hallmark of Lynch syndrome- associated tumors is MSI-H.

MSI-H和dMMR肿瘤无法准确修复细胞内的DNA。
MSI-H and dMMR tumors are unable to properly repair the DNA inside cells.

DMMR或MSI-H肿瘤状态由当地的实验室确定。
Assessment of dMMR or MSI-H tumor status was determined by local laboratories.

MSI-H和dMMR型肿瘤无法准确修复细胞内的DNA。
MSI-H and dMMR tumors are unable to properly repair the DNA inside cells.

因此，应对所有CRC患者进行dMMR或MSI-H状态的常规检查。
Routine testing to confirm dMMR or MSI-H status should be conducted for all CRC patients.

Dmmr或msi-h肿瘤状态的评估由当地实验室确定。
Assessment of dMMR or MSI-H tumor status was determined by local laboratories.

因此，应对所有CRC患者进行dMMR或MSI-H状态的常规检查。
Routine testing to determine MSI-H or dMMR status should be conducted for all CRC patients.

MSI-H和dMMR肿瘤会影响细胞内DNA的正常修复。
MSI-H and dMMR tumors contain abnormalities that affect the proper repair of DNA inside the cell.

大约15%的CRC患者和4-5%的mCRC患者具有MSI-H或dMMR生物标志物。
Approximately 15% of CRC patients and 4-5% of metastatic CRC patients have MSI-H or dMMR biomarkers.

MSI-H和dMMR癌症具有某些基因突变，可能对某些类型的治疗无效。
MSI-H and dMMR cancers have certain genetic mutations and may not respond to some types of treatment.

在子宫内膜癌中，这是非常适用的，因为28％的新诊断的子宫内膜癌是MSI-H。
In endometrial cancer, this is very applicable because 28% of newly diagnosed endometrial cancers are MSI-H.

DMMR或MSI-H转移性CRC患者不太可能受益于常规化疗，一般预后差。
Patients with dMMR or MSI-H metastatic CRC are less likely to benefit from conventional chemotherapy and typically have a poor prognosis.

与其他肿瘤相比，MSI-H肿瘤dMMR与更高频率的DNA突变，因此，高水平的异常抗原。
Compared with other tumors, dMMR and MSI-H tumors have a higher frequency of DNA mutations and, as a result, higher levels of abnormal antigens.

DMMR或MSI-HmCRC患者很难从传统的化疗中获益，且通常预后很差。
Patients with dMMR or MSI-H metastatic CRC are less likely to benefit from conventional chemotherapy and typically have a poor prognosis.

Checkmate142Ⅱ期临床试验是一个国际、多中心、开放的临床研究，入组的患者包括MSI-H和微卫星稳定的患者。
The open-label, international, phase 2 CheckMate-142 study enrolled patients with recurrent or mCRC, including MSI-H patients and microsatellite stable patients.

具有MSI-H或dMMR的mCRC患者不太可能从常规化疗中受益，并且通常具有不良预后。
Patients with dMMR or MSI-H metastatic CRC are less likely to benefit from conventional chemotherapy and typically have a poor prognosis.

我们在开发治疗MSI-H癌症的新疗法之前，我们首先需要明白什么因素帮助了癌细胞生存和增殖。
Before we can develop new treatments against MSI-H cancer cells, we first need to understand what it is that helps them to survive and thrive.

DMMR或MSI-HmCRC患者不大可能受益于常规化疗方案，通常预后非常差，存活率也低。
Patients with dMMR or MSI-H metastatic CRC are less likely to benefit from conventional chemotherapy and typically have a poor prognosis.

在一个后续的试验，称为keynote-177，调查人员将比较pembrolizumab标准治疗结直肠肿瘤dMMR或MSI-H患者。
In one follow-up trial, called KEYNOTE-177, investigators will compare pembrolizumab with standard therapy for patients with dMMR or MSI-H colorectal tumors.

最后，在85％的MSI-H应答者中，总肿瘤负荷减少≥50％，69％MSS的患者总肿瘤负荷减少≥50％。
Lastly, there was≥50% reduction or more in the total tumor burden among 85% of the MSI-H responders and 69% in those with MSS disease.

MSI-H/MMR-D在结直肠癌或子宫内膜癌中的存在促使临床医生对LS进行进一步的种系基因检测。
The presence of MSI-H/MMR-D in colorectal or endometrial cancer prompts clinicians to proceed with further germline genetic testing for LS.

研究人员发现，在MSI-H和MSI-ILS队列中（共66名患者），只有50％患有结肠直肠癌或子宫内膜癌。
The researchers found that among the MSI-H and MSI-I LS cohorts(66 patients in total), only 50 percent had colorectal or endometrial cancer.

直到最近，通过基于聚合酶链反应的微卫星不稳定性分析或MMR蛋白表达的免疫组织化学分析，对MSI-H/MMR-D进行了测试。
Until recently, testing for MSI-H/MMR-D has been done through a polymerase chain reaction- based microsatellite instability analysis or immunohistochemical analysis for MMR protein expression.